“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
— Warren Buffett
A long holding period can materially change the economics of an equity investment, especially when capital appreciation is paired with dividend reinvestment. For ResMed Inc. (NYSE: RMD), a $10,000 investment made on 09/02/2016 grew to $38,576.12 by 09/01/2026, assuming dividends were reinvested. That equates to a total return of 285.62% and an average annual return of 14.45%.
ResMed is best known for its sleep and respiratory care devices, including products used in the treatment of sleep apnea and other breathing-related conditions. That positioning has given the company exposure to a healthcare market supported by recurring demand, durable device replacement cycles, and a large installed base. Over a decade, those characteristics can matter as much as short-term market sentiment.
RMD 10-Year Return Details
| Start date: | 09/02/2016 |
|
|||
| End date: | 09/01/2026 | ||||
| Start price/share: | $67.06 | ||||
| End price/share: | $231.36 | ||||
| Starting shares: | 149.12 | ||||
| Ending shares: | 166.68 | ||||
| Dividends reinvested/share: | $17.53 | ||||
| Total return: | 285.62% | ||||
| Average annual return: | 14.45% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $38,576.12 | ||||
The result is straightforward: a $10,000 investment in ResMed in 2016 would have nearly quadrupled over the subsequent decade under a dividend reinvestment assumption. [These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
What Drove the 10-Year Return?
ResMed’s 10-year return came from two sources:
- Share price appreciation: the stock rose from $67.06 to $231.36 per share.
- Reinvested dividends: shareholders collected a cumulative $17.53 per share in dividends over the holding period, and those distributions were assumed to be reinvested.
This distinction matters. Price return shows what the stock did on its own, while total return captures the full effect of shareholder distributions. Over long periods, even a relatively modest dividend yield can make a measurable contribution when reinvested consistently.
Dividend Reinvestment and Share Growth
Under the reinvestment assumption used here, the initial 149.12 shares grew to 166.68 shares by the end of the period. That increase did not come from new capital contributions; it came from using cash dividends to purchase additional shares over time.
For companies that pay regular dividends, this mechanism can gradually expand an investor’s ownership stake. The effect is often easy to overlook because the dividend yield may appear small in any single year, but over a decade the compounding can become meaningful.
Current Yield and Yield on Cost
Based on the most recent annualized dividend rate of $2.64 per share, RMD has a current yield of approximately 1.14% using the ending share price of $231.36. Measured against the original 2016 purchase price of $67.06, that same dividend rate implies a yield on cost of 1.70%.
Yield on cost is a useful retrospective measure because it shows how a growing dividend stream relates to the original entry price. It does not replace current valuation analysis, but it does illustrate how time can improve the income profile of a successful long-term holding.
Why ResMed Has Been a Durable Compounder
ResMed operates in medical technology rather than in a highly cyclical commodity or discretionary market. Its business has historically benefited from several structural features:
- Non-discretionary demand: sleep apnea and respiratory care are tied to ongoing medical need rather than optional spending.
- Recurring revenue characteristics: masks, accessories, and related supplies can create repeat demand beyond the initial device sale.
- Installed-base economics: a large device footprint can support follow-on sales, patient monitoring, and ecosystem retention.
- Healthcare market resilience: demand drivers in respiratory care are often less sensitive to economic cycles than many other end markets.
Those qualities do not insulate the stock from valuation changes, competitive pressure, reimbursement dynamics, or product-cycle risk. They do, however, help explain why the company has been capable of generating long-duration shareholder returns.
Key Takeaway
ResMed’s 10-year return shows how a high-quality healthcare business can create substantial value when held over a full market cycle. In this case, the combination of share price appreciation and reinvested dividends turned $10,000 into $38,576.12, with an annualized return of 14.45%.
That outcome also underscores a broader point: over long periods, total return is driven not only by where a stock trades today, but by the durability of the underlying business, the consistency of cash distributions, and the power of compounding.
“Money is better than poverty, if only for financial reasons.” — Woody Allen
